Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Aspart Extension Study in Type 1 Diabetes
NCT01707134Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 1997
- Primary completion
- May 2000
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of insulin aspart in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Number of hypoglycaemic events. Started Sep 1997; status: completed.
02
Drugs
insulin aspart
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01707134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01707134.